These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 14573355)

  • 1. Sugar coating extends half-lives and improves effectiveness of cytokine hormones.
    Koury MJ
    Trends Biotechnol; 2003 Nov; 21(11):462-4. PubMed ID: 14573355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins.
    Sinclair AM; Elliott S
    J Pharm Sci; 2005 Aug; 94(8):1626-35. PubMed ID: 15959882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of therapeutic protein in vivo activities through glycoengineering.
    Elliott S; Lorenzini T; Asher S; Aoki K; Brankow D; Buck L; Busse L; Chang D; Fuller J; Grant J; Hernday N; Hokum M; Hu S; Knudten A; Levin N; Komorowski R; Martin F; Navarro R; Osslund T; Rogers G; Rogers N; Trail G; Egrie J
    Nat Biotechnol; 2003 Apr; 21(4):414-21. PubMed ID: 12612588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and characterization of novel erythropoiesis stimulating protein (NESP).
    Egrie JC; Browne JK
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):3-10. PubMed ID: 11308268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of erythropoietin production with controlled glycosylation-PEGylated erythropoietin produced in glycoengineered Pichia pastoris.
    Nett JH; Gomathinayagam S; Hamilton SR; Gong B; Davidson RC; Du M; Hopkins D; Mitchell T; Mallem MR; Nylen A; Shaikh SS; Sharkey N; Barnard GC; Copeland V; Liu L; Evers R; Li Y; Gray PM; Lingham RB; Visco D; Forrest G; DeMartino J; Linden T; Potgieter TI; Wildt S; Stadheim TA; d'Anjou M; Li H; Sethuraman N
    J Biotechnol; 2012 Jan; 157(1):198-206. PubMed ID: 22100268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of rHuEPO biological activity: the role of carbohydrate.
    Elliott S; Egrie J; Browne J; Lorenzini T; Busse L; Rogers N; Ponting I
    Exp Hematol; 2004 Dec; 32(12):1146-55. PubMed ID: 15588939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introduction. Improving the standard of care in the management of cancer-related anaemia: focus on darbepoetin alfa, a novel erythropoiesis-stimulating protein.
    Glaspy J
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):1-2. PubMed ID: 11308267
    [No Abstract]   [Full Text] [Related]  

  • 8. Glycosylation-modified erythropoietin with improved half-life and biological activity.
    Su D; Zhao H; Xia H
    Int J Hematol; 2010 Mar; 91(2):238-44. PubMed ID: 20131103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prolonged half-lives of new erythropoietin derivatives via peptide addition.
    Lee DE; Son W; Ha BJ; Oh MS; Yoo OJ
    Biochem Biophys Res Commun; 2006 Jan; 339(1):380-5. PubMed ID: 16314154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of sialic acids on the pharmacokinetics of a PEGylated erythropoietin.
    Liu L; Li H; Hamilton SR; Gomathinayagam S; Rayfield WJ; van Maanen M; Yin KC; Hong L; Prueksaritanont T
    J Pharm Sci; 2012 Dec; 101(12):4414-8. PubMed ID: 22987365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current state and perspectives on erythropoietin production.
    Lee JS; Ha TK; Lee SJ; Lee GM
    Appl Microbiol Biotechnol; 2012 Sep; 95(6):1405-16. PubMed ID: 22820523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report.
    Heatherington AC; Schuller J; Mercer AJ
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):11-6. PubMed ID: 11308269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia.
    Macdougall IC
    Curr Hematol Rep; 2005 Nov; 4(6):436-40. PubMed ID: 16232379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sugar in erythropoietin: clinical and forensic implications.
    Bunn HF
    Blood; 2002 Mar; 99(5):1503. PubMed ID: 11861258
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-erythropoietin and anti-thrombopoietin antibodies induced after administration of recombinant human erythropoietin.
    Shin SK; Pack SP; Oh JG; Kang NK; Chang MH; Chung YH; Kim SJ; Lee JW; Heo TH
    Int Immunopharmacol; 2011 Dec; 11(12):2237-41. PubMed ID: 22051973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The structure, biology and potential therapeutic applications of recombinant thrombopoietin.
    Lok S; Foster DC
    Stem Cells; 1994 Nov; 12(6):586-98. PubMed ID: 7881359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and characterization of novel erythropoiesis stimulating protein (NESP).
    Egrie JC; Browne JK
    Nephrol Dial Transplant; 2001; 16 Suppl 3():3-13. PubMed ID: 11402085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of recombinant human erythropoietin and interleukin-3 on erythropoietic recovery from acute anemia.
    Rosen BS; Levine EA; Egrie JC; Sehgal LR; Greenberg R; Rosen AL; Levine HD; Gould SA
    Exp Hematol; 1993 Oct; 21(11):1487-91. PubMed ID: 8405228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin--improving the quality of life of dialysis patients.
    Kionka C
    J Biotechnol; 1995 Nov; 43(1):73-4. PubMed ID: 8573324
    [No Abstract]   [Full Text] [Related]  

  • 20. Biological roles for the second domain of thrombopoietin.
    Foster D; Lok S
    Stem Cells; 1996; 14 Suppl 1():102-7. PubMed ID: 11012208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.